Master Alliance Provisions Guide (MAPGuide)

AXA Prime Impact Master Fund – Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement

  • Equitable Access | Affordable pricing

<p class=”p1“><span style=”textdecoration: underline;”><strong>4. ProgramRelated Investment Requirements<span class=”Appleconvertedspace“> span>strong>span>p>
<p class=”p1“>In consideration of the Investor making, or having made, the Investment on the terms and conditions stated herein and in the Investment Documents, and for other good and valuable consideration, the undersigned hereby agree as follows:<span class=”Appleconvertedspace“> span>p>
<p class=”p1“><strong>(b) Global Access Commitments<span class=”Appleconvertedspace“> span>strong>p>
<p class=”p1“>(i) Beginning on the date of this Global Health Agreement, the Company shall conduct the following activities to advance the Global Health Objectives during the Term:<span class=”Appleconvertedspace“> span>p>
<p>(2) The Company shall make Program Products available to nonprofit organizations and publicsector purchasers in Target Countries (“<em><strong>Global Health Purchasersstrong>em>”) at a price of no more than 30% above the Companys COGS, in Low-Income Countries and in LowMiddleIncome Countries, if approved by the Global Access Committee (as defined below); provided, however, that any nonprofit organization and publicsector purchaser located in Brazil, India, South Africa and Mexico shall need to be approved by the Global Access Committee before qualifying as aGlobal Health Purchaserwithin the terms of this Global Health Agreement.p>